Biomet Spine Sales Lag In Q4; Firm Looks To Differentiated Devices

Biomet's spine sales rose just 1% to $62 million last quarter, but the company is confident growth will pick up as it puts more emphasis on "highly differentiated" devices, CEO Jeffrey Binder said during a July 13 call reporting fourth-quarter earnings for Biomet's fiscal year 2010, ended May 31